Intermediate Levels of Pre-Existing Protective Antibody Allow Priming of Protective T Cell Immunity against Influenza.


Journal

Journal of immunology (Baltimore, Md. : 1950)
ISSN: 1550-6606
Titre abrégé: J Immunol
Pays: United States
ID NLM: 2985117R

Informations de publication

Date de publication:
01 03 2023
Historique:
received: 01 06 2022
accepted: 23 12 2022
pmc-release: 01 03 2024
pubmed: 17 1 2023
medline: 10 3 2023
entrez: 16 1 2023
Statut: ppublish

Résumé

Overcoming interfering impacts of pre-existing immunity to generate universally protective influenza A virus (IAV)-specific T cell immunity through vaccination is a high priority. In this study, we passively transfer varied amounts of H1N1-IAV-specific immune serum before H1N1-IAV infection to determine how different levels of pre-existing Ab influence the generation and protective potential of heterosubtypic T cell responses in a murine model. Surprisingly, IAV nucleoprotein-specific CD4 and CD8 T cell responses are readily detected in infected recipients of IAV-specific immune serum regardless of the amount transferred. When compared with responses in control groups and recipients of low and intermediate levels of convalescent serum, nucleoprotein-specific T cell responses in recipients of high levels of IAV-specific serum, which prevent overt weight loss and reduce peak viral titers in the lungs, are, however, markedly reduced. Although detectable at priming, this response recalls poorly and is unable to mediate protection against a lethal heterotypic (H3N2) virus challenge at later memory time points. A similar failure to generate protective heterosubtypic T cell immunity during IAV priming is seen in offspring of IAV-primed mothers that naturally receive high titers of IAV-specific Ab through maternal transfer. Our findings support that priming of protective heterosubtypic T cell responses can occur in the presence of intermediate levels of pre-existing Ab. These results have high relevance to vaccine approaches aiming to incorporate and evaluate cellular and humoral immunity towards IAV and other viral pathogens against which T cells can protect against variants escaping Ab-mediated protection.

Identifiants

pubmed: 36645384
pii: 237680
doi: 10.4049/jimmunol.2200393
pmc: PMC9998374
mid: NIHMS1861847
doi:

Substances chimiques

Influenza Vaccines 0
Antibodies, Viral 0
Immune Sera 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

628-639

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI165406
Pays : United States
Organisme : NICHD NIH HHS
ID : R21 HD093948
Pays : United States

Informations de copyright

Copyright © 2023 by The American Association of Immunologists, Inc.

Références

Cell. 2021 Feb 18;184(4):861-880
pubmed: 33497610
J Immunol. 2001 Jun 15;166(12):7437-45
pubmed: 11390496
J Immunol. 1985 Mar;134(3):1994-8
pubmed: 3155776
Lancet. 1979 Jan 6;1(8106):33-5
pubmed: 83475
Science. 2021 Dec 03;374(6572):abm0829
pubmed: 34648302
J Virol. 2011 Nov;85(22):11995-2000
pubmed: 21880755
J Immunol. 2007 Jan 15;178(2):1030-8
pubmed: 17202366
J Infect Dis. 2011 Sep 15;204(6):845-53
pubmed: 21846636
Lancet Infect Dis. 2016 Aug;16(8):942-51
pubmed: 27061888
Vaccine. 2021 Mar 12;39(11):1598-1608
pubmed: 33612341
Lancet Infect Dis. 2009 Dec;9(12):784-8
pubmed: 19879807
Sci Transl Med. 2013 Aug 28;5(200):200ra114
pubmed: 23986398
Emerg Infect Dis. 2006 Jan;12(1):48-54
pubmed: 16494717
Nat Med. 2010 May;16(5):558-64, 1p following 564
pubmed: 20436484
Nat Med. 2012 Jan 29;18(2):274-80
pubmed: 22286307
Nat Rev Microbiol. 2021 Jul;19(7):409-424
pubmed: 34075212
Nat Rev Immunol. 2021 Jun;21(6):382-393
pubmed: 33875867
mBio. 2017 Mar 21;8(2):
pubmed: 28325769
Vaccine. 2020 Jan 3;38(1):20-28
pubmed: 31672332
J Immunol. 2004 May 1;172(9):5553-60
pubmed: 15100298
Mol Cell. 2017 Feb 2;65(3):403-415.e8
pubmed: 28132841
Nat Commun. 2021 Dec 15;12(1):7288
pubmed: 34911947
Cold Spring Harb Perspect Med. 2021 Nov 1;11(11):
pubmed: 32988981
J Infect Dis. 2023 Feb 1;227(3):381-390
pubmed: 35199825
Lancet. 2012 Dec 15;380(9859):2095-128
pubmed: 23245604
Cell. 2020 Nov 12;183(4):996-1012.e19
pubmed: 33010815
Nat Med. 2019 Apr;25(4):591-596
pubmed: 30886409
Nat Rev Immunol. 2012 Jan 20;12(2):136-48
pubmed: 22266691
Lancet. 2018 Mar 31;391(10127):1285-1300
pubmed: 29248255
Curr Opin Immunol. 2018 Aug;53:187-195
pubmed: 29890370
Am J Reprod Immunol. 2022 Jul;88(1):e13550
pubmed: 35452552
Nat Commun. 2014 Nov 05;5:5377
pubmed: 25369785
J Infect. 2016 Jul 5;72 Suppl:S83-90
pubmed: 27233120
J Immunol. 2008 Feb 15;180(4):2562-72
pubmed: 18250467
Cell Rep. 2022 Feb 15;38(7):110388
pubmed: 35172138
J Immunol. 2014 Jan 1;192(1):200-5
pubmed: 24273000
J Immunol. 1994 Feb 15;152(4):1653-61
pubmed: 8120375
Cell. 2022 Apr 28;185(9):1588-1601.e14
pubmed: 35413241
EClinicalMedicine. 2019 Jul 26;13:21-30
pubmed: 31517260
Immunity. 2021 Sep 14;54(9):2133-2142.e3
pubmed: 34453880
J Exp Med. 1978 Apr 1;147(4):1236-52
pubmed: 306410
Science. 2014 Nov 21;346(6212):996-1000
pubmed: 25414313
J Virol. 1987 May;61(5):1375-83
pubmed: 2952806
Clin Vaccine Immunol. 2011 Sep;18(9):1519-23
pubmed: 21813667
Clin Infect Dis. 2018 Oct 30;67(suppl_1):S57-S65
pubmed: 30376095
J Clin Invest. 1997 Nov 1;100(9):2371-5
pubmed: 9410917
Cell. 2022 Mar 3;185(5):847-859.e11
pubmed: 35139340
Emerg Themes Epidemiol. 2021 Oct 21;18(1):15
pubmed: 34674730
Nat Med. 2013 Oct;19(10):1305-12
pubmed: 24056771
Nat Med. 2006 Oct;12(10):1203-7
pubmed: 16964257
J Virol. 2011 Dec;85(24):13310-21
pubmed: 21976658
Vaccine. 2008 Apr 16;26(17):2062-72
pubmed: 18378366
Immunity. 2010 Jan 29;32(1):79-90
pubmed: 20096607
PLoS One. 2009;4(5):e5538
pubmed: 19440239
J Biomed Sci. 2014 Nov 18;21:99
pubmed: 25407417
Science. 2010 Aug 27;329(5995):1060-4
pubmed: 20647428
Front Immunol. 2014 Sep 16;5:446
pubmed: 25278941
Best Pract Res Clin Obstet Gynaecol. 2021 Oct;76:66-82
pubmed: 33129673
Vaccine. 2021 Jul 30;39(33):4628-4640
pubmed: 34226103
Br Med Bull. 1979 Jan;35(1):69-75
pubmed: 367490
Front Immunol. 2015 Feb 24;6:79
pubmed: 25759693
J Hyg (Lond). 1972 Dec;70(4):767-77
pubmed: 4509641
J Exp Med. 1998 May 4;187(9):1383-93
pubmed: 9565631
Sci Immunol. 2021 May 25;6(59):
pubmed: 34035118
J Immunol. 1991 Mar 15;146(6):1972-8
pubmed: 2005388
Am J Respir Cell Mol Biol. 2011 May;44(5):692-9
pubmed: 20616357
J Clin Invest. 2012 Aug;122(8):2847-56
pubmed: 22820287
Infect Immun. 1984 Jan;43(1):202-5
pubmed: 6606624
Nat Rev Immunol. 2020 Oct;20(10):633-643
pubmed: 32782358
Vaccine. 2012 Dec 7;30(51):7407-10
pubmed: 22643217
Virol J. 2017 Jun 26;14(1):123
pubmed: 28651593
J Immunol. 2008 Jan 1;180(1):454-63
pubmed: 18097047
Proc Natl Acad Sci U S A. 2019 Jul 23;116(30):15194-15199
pubmed: 31296560
PLoS Pathog. 2020 Nov 19;16(11):e1009010
pubmed: 33211756
J Immunol. 2001 Apr 1;166(7):4627-33
pubmed: 11254721
Cell Rep. 2022 Apr 12;39(2):110632
pubmed: 35417685
Sci Transl Med. 2015 Dec 2;7(316):316ra192
pubmed: 26631631
Science. 2012 Dec 21;338(6114):1634-7
pubmed: 23180776
Nat Commun. 2020 Sep 11;11(1):4566
pubmed: 32917903
J Gen Virol. 2010 Jul;91(Pt 7):1743-53
pubmed: 20335492
PLoS Pathog. 2022 Mar 10;18(3):e1010395
pubmed: 35271686
J Virol. 2015 Mar;89(6):3308-17
pubmed: 25589639
J Lab Clin Med. 1988 Nov;112(5):634-40
pubmed: 3183495
J Infect Dis. 2006 Jan 1;193(1):49-53
pubmed: 16323131
Curr Protoc Immunol. 2001 May;Chapter 19:Unit 19.11
pubmed: 18432752
Immunol Rev. 2013 Sep;255(1):149-64
pubmed: 23947353
Curr Protoc Microbiol. 2009 May;Chapter 15:Unit 15G.3
pubmed: 19412911
J Virol. 2000 Apr;74(8):3486-93
pubmed: 10729122
J Immunol. 2013 Aug 1;191(3):1001-5
pubmed: 23794632
JCI Insight. 2017 Dec 21;2(24):
pubmed: 29263304
Vaccines (Basel). 2020 Nov 16;8(4):
pubmed: 33207559
J Exp Med. 2014 Aug 25;211(9):1707-14
pubmed: 25135297
J Exp Med. 1977 Mar 1;145(3):557-68
pubmed: 233901
Cold Spring Harb Perspect Biol. 2021 Nov 1;13(11):
pubmed: 33903157
J Exp Med. 2013 Jul 29;210(8):1493-500
pubmed: 23857983
J Virol. 2011 Mar;85(6):2695-702
pubmed: 21228239
J Immunol. 2006 Oct 15;177(8):5317-27
pubmed: 17015717
PLoS Pathog. 2019 Aug 14;15(8):e1007989
pubmed: 31412088
Nat Commun. 2018 Dec 21;9(1):5427
pubmed: 30575715
Clin Immunol. 2006 Apr;119(1):87-94
pubmed: 16386960
Nature. 2021 Jul;595(7868):572-577
pubmed: 34044428
PLoS One. 2012;7(3):e33428
pubmed: 22432020
Cell Rep. 2017 Apr 4;19(1):114-124
pubmed: 28380351

Auteurs

Terry Ng (T)

Division of Immunity and Pathogenesis, Burnett School of Biomedical Sciences College of Medicine, University of Central Florida, Orlando, FL.

Valeria Flores-Malavet (V)

Division of Immunity and Pathogenesis, Burnett School of Biomedical Sciences College of Medicine, University of Central Florida, Orlando, FL.

Mishfak A M Mansoor (MAM)

Division of Immunity and Pathogenesis, Burnett School of Biomedical Sciences College of Medicine, University of Central Florida, Orlando, FL.

Andrea C Arvelo (AC)

Division of Immunity and Pathogenesis, Burnett School of Biomedical Sciences College of Medicine, University of Central Florida, Orlando, FL.

Kunal Dhume (K)

Division of Immunity and Pathogenesis, Burnett School of Biomedical Sciences College of Medicine, University of Central Florida, Orlando, FL.

Emily Prokop (E)

Division of Immunity and Pathogenesis, Burnett School of Biomedical Sciences College of Medicine, University of Central Florida, Orlando, FL.

K Kai McKinstry (KK)

Division of Immunity and Pathogenesis, Burnett School of Biomedical Sciences College of Medicine, University of Central Florida, Orlando, FL.

Tara M Strutt (TM)

Division of Immunity and Pathogenesis, Burnett School of Biomedical Sciences College of Medicine, University of Central Florida, Orlando, FL.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH